|
Envelope surface glycoprotein gp120
|
env
|
HIV-1 CN54, JRFL, and Ada Env (gp120) upregulates IL-6, CCL2, CCL4, CXCL8, and IL-1b through TLR4 and CCR5 induction in monocyte derived macrophages and hepatic stellate cells because treatment with an anti-TLR4 antibody mitigated the response |
PubMed
|
|
env
|
HIV-1 IIIB Env (gp120) upregulates production of TNF (TNF-a), IL-17A, CCL2 (MCP1), CCL5 (RANTES), IL6, IL10, CXCL8 (IL8), CXCL1 (GRO-a), and CCL1 (I309) in stimulated monocyte derived macrophages |
PubMed
|
|
env
|
Cytokines induced in vitro by HIV-1 gp120 in normal peripheral blood mononuclear cells (PBMC) include interferon-alpha (IFN-alpha) and IFN-gamma, tumor necrosis factor-alpha (TNF-alpha), IL-6, IL-10, IL-1 alpha and IL-1 beta |
PubMed
|
|
env
|
Curcumin, a potent and safe anti-inflammatory compound, inhibits HIV-1 gp120-mediated upregulation of the proinflammatory cytokines TNF-alpha and IL-6, and the chemokines IL-8, RANTES, and IP-10 in primary human genital epithelial cells |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-6 activates STAT3 in primary human monocyte-derived dendritic cells |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-6 is regulated by p38 MAPK, IkappaBalpha, and p65 NF-kappaB activation in primary human monocyte-derived dendritic cells |
PubMed
|
|
env
|
Interaction of HIV-1 gp120 with CCR5 upregulates IL-6 expression in primary human monocyte-derived dendritic cells |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-6 and MCP-1 is partially responsible for the impairment of barrier function in human retinal pigment epithelial cells |
PubMed
|
|
env
|
HIV-1 gp120 stimulates monocytes to release TNF-alpha, IL-1 beta, IL-6, and granulocyte-macrophage-CSF, and this effect can be blocked with soluble CD4 |
PubMed
|
|
env
|
HIV-1 gp120 upregulates the expression of IL-6 and IL-8 via the p38 signaling pathway and the PI3K/Akt signaling pathway in astrocytes |
PubMed
|
|
env
|
HIV-1 gp120-induced expansion of myeloid derived suppressor cells is dependent on the upregulation of IL-6 by gp120 |
PubMed
|
|
env
|
HIV-1 gp120 recruits SOCS-3 through IL-10 activation for suppressing IL-6 and IL-6 dependent STAT3 in immature dentritic cells |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-10 inhibits STAT3 activation, leading to suppress HIV-1 Nef-induced IL-6 secretion in immature dentritic cells |
PubMed
|
|
env
|
HIV-1 gp120 downregulates HIV-1 Nef dependent IL-6 release, which requires the interaction of gp120 with DC-SIGN |
PubMed
|
|
env
|
HIV-1 gp120 induces the release of cytokines MIP-1 alpha, MIP-1 beta, IL-6, IL-10, and TNF-alpha in immature dentritic cells |
PubMed
|
|
env
|
HIV-1 gp120 inhibits CpG-A-induced secretion of TNF-alpha, IL-6, and IP-10 proteins in plasmacytoid dendritic cells and PBMCs |
PubMed
|
|
env
|
HIV-1 gp120 induces a time-dependent IL-6 upregulation by translocating NF-kappaB1 from cytoplasm to nucleus in human astrocyte cells |
PubMed
|
|
env
|
HIV-1 gp120 inhibits TLR9-mediated upregulation of CD83 and the secretion of inflammatory cytokines TNF-alpha and IL-6, and chemokine IP10 in plasmacytoid dendritic cells (pDC) |
PubMed
|
|
env
|
Treatment of human hepatic stellate cells with gp120 significantly increases secretion and gene expression of CCL2, metalloprotease-1 and interleukin-6. Gp120 also induces activation of Akt, NF-kappaB, and p38(MAPK) |
PubMed
|
|
env
|
HIV-1 gp120 activates human brain micro vascular endothelial cells (HBMEC) via CD4 in upregulating ICAM-1 and VCAM-1 expression, IL-6 secretion and increased monocyte transmigration across monolayers |
PubMed
|
|
Envelope surface glycoprotein gp160, precursor
|
env
|
HIV-1 gp160 induces interleukin-6 production in CD4+ T cells |
PubMed
|
|
env
|
HIV-1 gp140 monomer and trimer induce a time-dependent IL-6 upregulation in human astrocyte cells |
PubMed
|
|
env
|
Chimeric HIV-1 gp140 - CD40L trimers can target and activate dendritic cells to release IL-6, IL-10 and IL-12 |
PubMed
|
|
Envelope transmembrane glycoprotein gp41
|
env
|
The HIV-1 gp41 transmembrane domain inhibits TLR2-induced activation of ERK1/2, and secretion of TNF-alpha, MCP-1, and IL-6 |
PubMed
|
|
env
|
A synthetic peptide corresponding to the immunosuppressive domain (amino acids 574-592) of HIV-1 gp41 inhibits activation of PBMCs and upregulates the expression of IL-6 in peptide-treated PBMCs |
PubMed
|
|
env
|
HIV-1 gp41 induces significant IL-6 production by human monocytic cells; IL-10 inhibits gp41-induced IL-6 production and reduces the expression of IL-6 mRNA |
PubMed
|
|
env
|
Mutations L576A, Q577A, A578G, A582G, V583A, and E584A in the conserved immunosuppressive domain (amino acids 576-589) of HIV-1 gp41 significantly downregulate IL-6 release from human PBMCs |
PubMed
|
|
env
|
PWM, LPS, IFN-gamma and IL-6 can increase HIV-1 gp41 binding to human B cells |
PubMed
|
|
Nef
|
nef
|
HIV-1 Nef induces IL6 and CXCL8 (IL8) expression in a PIK3-PKC dependent, AKT independent manner |
PubMed
|
|
nef
|
HIV-1 Nef induces IL6 and IL8 expression through the NF-kappaB pathway |
PubMed
|
|
nef
|
HIV-1 Nef treatment induces IL6 and IL8 production in SVGA cells and primary human fetal astrocytes |
PubMed
|
|
nef
|
HIV-1 Tat and Nef combination treatment induces release of both IL-6 and IL-8 in human mesenchymal stem cells |
PubMed
|
|
nef
|
The expression of HIV-1 Nef in primary human monocyte-derived macrophages (MDM) induces a significant increase in the concentration of IL-6 |
PubMed
|
|
nef
|
HIV-1 gp120-induced release of IL-10 inhibits STAT3 activation, leading to suppress HIV-1 Nef-induced IL-6 secretion in immature dentritic cells |
PubMed
|
|
nef
|
HIV-1 gp120 downregulates HIV-1 Nef dependent IL-6 release, which requires the interaction of gp120 with DC-SIGN in immature dentritic cells |
PubMed
|
|
nef
|
HIV-1 Nef synergizes with IL-6 to activate the AKT pathway promoting angiogenesis and tumorigenesis in achicken chorioallantoic membrane model and nude mice |
PubMed
|
|
nef
|
HIV-1 Nef synergizes with IL-6 to upregulate expression of basic fibroblast growth factor and cyclin D1 in NIH3T3-induced tissues |
PubMed
|
|
nef
|
HIV-1 Nef synergizes with IL-6 to enhance vascular tube formation, cell proliferation, VEGF expression, and phosphorylated AKT activation in human umbilical vein endothelial cells |
PubMed
|
|
nef
|
HIV-1 Nef inhibits IFN-gamma-induced apoptosis and upregulates TNF-alpha, IL-6 and MIP-3alpha production by Caco-2 cells while downregulates IL-10 production |
PubMed
|
|
nef
|
Both the myristoylation site and the acidic cluster in HIV-1 Nef are required for the activation of NF-kappaB, which induces upregulation of TNFalpha and IL6 expression |
PubMed
|
|
nef
|
Intracisternal HIV-1 Nef injection upregulates levels of IL-6, TNF-alpha, and IFN-gamma in rat cerebrospinal fluid |
PubMed
|
|
nef
|
HIV-1 Nef expression by immature human and macaque dendritic cells (DCs) upregulates IL-6, IL-12, TNF-alpha, CXCL8, CCL3, and CCL4 release, but without upregulating co-stimulatory and other molecules characteristic of mature DCs |
PubMed
|
|
nef
|
Treatment of human PBMC and PBL with soluble HIV-1 Nef upregulates IL-6 production |
PubMed
|
|
Pr55(Gag)
|
gag
|
MVA-gag induces a significant release of cytokines such as IL-2R, IL-6, IL-8, TNF-alpha, IFN-gamma, MCP-1, MIP-1alpha, MIP-1beta, and RANTES by the infected monocyte-derived dendritic cells in comparison with uninfected cells |
PubMed
|
|
gag
|
Depletion of HIV-specific CD8(+)/IL-10(+) cells from PBMCs leads to upregulation of CD38 on CD14(+) monocytes together with increased IL-6 production in response to HIV-1 gag stimulation |
PubMed
|
|
gag
|
HIV-1 Gag virus-like particles expressed by recombinant baculoviruses activate human PBMC to release IL-6 in a dose and time dependent manner |
PubMed
|
|
gag
|
The Matrix protein of HIV-1 Gag increases IL-6 production in placental mononuclear cells |
PubMed
|
|
Tat
|
tat
|
HIV-1 Tat upregulates IL6 protein expression in human monocytes and monocyte-derived dendritic cells in a TLR4-CD14-MD2 dependent manner |
PubMed
|
|
tat
|
Human microglia cells treated with HIV-1 clade C Tat show more significant upregulation of IL-6 and TNF-alpha, and higher NF-kappaB activation as compared to clade B Tat-treated cells |
PubMed
|
|
tat
|
HIV-1 Tat and Nef combination treatment induces release of both IL-6 and IL-8 in human mesenchymal stem cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates IL-6 expression in monocytes, astrocytes, microglial cells, human brain endothelial cells, THP-1 and Jurkat T-cells, MC3 B-cells, HeLa, and cells from Kaposi's sarcoma lesions |
PubMed
|
|
tat
|
HIV-1 Tat-induced upregulation of IL-6 in a time-dependent manner involves NF-kappaB and AP-1 transcription factors, activation of the p38 MAPK beta and delta subunits, and PI3K/Akt pathway in astrocytes |
PubMed
|
|
tat
|
Astrocyte cultures treated with morphine and HIV-1 Tat show exaggerated increases in chemokine release, including monocyte chemoattractant protein-1 (MCP-1), RANTES, and IL-6 |
PubMed
|
|
tat
|
Upregulation of IL-6 by HIV-1 Tat in human brain endothelial cells is mediated through activation of protein kinase C (PK-C) and cAMP-dependent protein kinase (PK-A) |
PubMed
|
|
tat
|
HIV-1 Tat inhibits CpG-A-induced secretion of TNF-alpha, IL-6, and IP-10 proteins in plasmacytoid dendritic cells and PBMCs |
PubMed
|
|
tat
|
LRRK2 is involved in HIV-1 Tat-induced cytokine TNF-alpha, IL-6, and MCP-1 expression in microglia cells |
PubMed
|
|
tat
|
HIV-1 Tat significantly decreases TNF-alpha and IL-6 secretion but increases IL-4 levels in human hepatocellular carcinoma cells |
PubMed
|
|
tat
|
HIV-1 Tat downregulates the expression of adiponectin protein and upregulates the expression of IL-6, IL-8, and MCP-1 proteins in human SGBS preadipocytes |
PubMed
|
|
tat
|
Monocytes treated with HIV-1 clade B Tat show significant upregulation of proinflammatory cytokines, IL-6 and TNF-alpha, as compared to clade C Tat-treated cultures |
PubMed
|
|
tat
|
Sulfated polymannuroguluronate (SPMG) significantly reverses HIV-1 Tat-induced release of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 in THP-1 cells |
PubMed
|
|
tat
|
Ectopic expression of HIV-1 Tat induces the production of human IL-6 (huIL-6) and its receptor (huIL-6Ra) and activates STAT3 signaling; these effects are involved in Tat-mediated activation of Kaposi's sarcoma-associated herpes virus (KSHV) replication |
PubMed
|
|
tat
|
Treatment of T lymphocytes with IL-2, IL-6 and TNFalpha increases CDK9 and cyclin T1 protein levels, suggesting a mechanism for activation of HIV-1 Tat function and reactivation of HIV-1 in CD4+ T lymphocytes harboring a latent provirus |
PubMed
|
|
tat
|
Hydroxyurea and IL-6 synergistically enhance HIV-1 Tat activation of HIV-1 LTR-driven transcription via the Sp1 binding site |
PubMed
|
|
tat
|
HIV-1 Tat protein upregulates expression of IL-6 and IL-8 in human breast cancer cells by an NF-kappaB-dependent pathway |
PubMed
|
|
tat
|
IL-6 and IL-6 receptor are upregulated in human epithelial cells by HIV-1 Tat treatment |
PubMed
|
|
tat
|
HIV-1 Tat upregulates IL-6 expression by transactivating the IL-6 promoter, an effect mediated through enhancement of CAAT enhancer-binding protein (C/EBP; nuclear factor-IL-6) DNA binding activity |
PubMed
|
|
Vpr
|
vpr
|
Treatment of human primary astrocytes with HIV-1 Vpr upregulates secretion of IL6, CXCL8 (IL-8), MCP-1, and MIF and downregulates secretion of serpin E1, a serine proteinase inhibitor (known as PAI-1) |
PubMed
|
|
vpr
|
HIV-1 Vpr induces IL6 production via activation of MAPK p38 |
PubMed
|
|
vpr
|
HIV-1 Vpr induced upregulation of IL6 involves PI3K/Akt mediated activation of NFKB1 (NF-kappaB) in astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr upregulation of IL6 involves NFKB1 (NF-kappaB) |
PubMed
|
|
vpr
|
HIV-1 Vpr enhances the secretion of IL6 from human fetal astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr upregulates the expression of IL6 mRNA in human fetal astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr upregulates the expression of IL6 mRNA in SVGA in a dose-dependent manner |
PubMed
|
|
vpr
|
HIV-1 Vpr upregulates the expression of IL6 mRNA in SVGA astrocytes in a time dependent fashion |
PubMed
|
|
vpr
|
HIV-1 Vpr enhances the secretion of IL6 from SVGA astrocytes in a time dependent fashion |
PubMed
|
|
vpr
|
HIV-1 involves the JUN (AP-1) transcription factor in the induction of IL6 in astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr involves the CEBPD (C/EBP-delta) transcription factor in the induction of IL6 in astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr-mediated regulation of IL6 involves MAPK8 (Jnk-MAPK8) in astrocytes |
PubMed
|
|
vpr
|
Vpr-mediated upregulation of IL6 involves p38-MAPK11 (beta isoform of p38-MAPK) in astrocytes |
PubMed
|
|
vpr
|
Soluble HIV-1 Vpr induces a markedly reduced expression of IL6 in monocytoid cells |
PubMed
|
|
vpr
|
Concurrent exposure of HIV-1 Vpr with HCV core protein causes higher IL6 expression than HIV-1 Vpr-treated human fetal microglia |
PubMed
|
|
vpr
|
HIV-1 Vpr-induced IL6 production depends on the activation of NFkappaB and the involvement of C/EBP-beta, TLR4, and MyD88 |
PubMed
|
|
vpr
|
HIV-1 Vpr upregulates IL6 expression in primary macrophages and in A549 cells |
PubMed
|
|
capsid
|
gag
|
Unactivated memory CD4+ T cells infected by HIV-1 in the presence of IL-2 and IL-15 alone or IL-6/IL-7/TNF-alpha combination, upregulate granzyme B and HIV-1 CA production |
PubMed
|
|
gag
|
PLA-p24-loaded human monocyte-derived dendritic cells enhance the secretion of MIP-1beta, IL-6, IL-8, and TNF-alpha in comparison with PLA-loaded cells alone |
PubMed
|
|
matrix
|
gag
|
HIV-1 MA natural variant S75X upregulates the expression of two cyclins D2 and D3, and induces significant release of cytokine IL-6 in both Epstein-Barr virus (EBV)-infected primary and fully transformed B-lymphocytes |
PubMed
|
|
gag
|
HIV-1 Matrix upregulates IL-6 production in placental mononuclear cells |
PubMed
|